There's still time to buy...
Two weeks ago, my analyst Jeff Havenstein made the case for higher oil prices. He said supply was too low, and the COVID-19 Omicron variant wouldn't wreck demand. That meant the recent dip in oil gave long-term-minded investors a great entry point.
Since he wrote this, the price of oil is up 7%.
But just recently, the International Energy Agency ("IEA") trimmed its forecast for oil demand this year and the next by 100,000 barrels per day.
The reason? The IEA said it expects the surge in coronavirus cases to thwart the recovery in global demand. Specifically, Omicron would hurt air travel.
This might scare some folks out of oil – but only if you just read the headline. You have to read further...
According to the IEA's monthly market report, "The surge in new COVID-19 cases is expected to temporarily slow, but not upend, the recovery in oil demand that is underway."
Like Jeff mentioned two weeks ago, there could be some short-term volatility in oil. Folks are going to be fearful with Omicron pushing cases higher. But, as Jeff explained, it would just be temporary noise.
As I've said before, I think Omicron is just hype. Mutations that spread fast – which apparently this one does – rarely make a virus more deadly.
I agree that the long-term case for oil is still there. It's just simple economics... Supply is far too low, and demand is recovering. That's a recipe for higher prices.
Jeff says there's still time to buy oil stocks if you haven't already.
Now, I'm no stranger to investing through crises...
I started working for my publisher Stansberry Research in 2008. While I was a Wall Street veteran, working for banks like Goldman Sachs and Chase Manhattan, I first started writing for Stansberry about health topics like the importance of olive oil and sunshine. (And by the way, I still continue to share health tips in this newsletter.)
You see, I have a unique background that includes years on Wall Street and also years in the medical field. After I left Wall Street, I earned my MD from the University of North Carolina at Chapel Hill and eventually became a board-eligible eye surgeon.
Ever since 2008, I've been writing about health as well as sharing investment ideas. And my role has grown over the years...
We launched Retirement Millionaire in the depths of the 2008 financial crisis. Again, the idea was that folks would hear not only from an MD, but also from the same guy with an MBA and years of experience on Wall Street.
During the panic of the Great Recession, I even convinced my good friend and founder of Stansberry Research, Porter Stansberry, that it was the ideal time to sell options.
If you know anything about option selling, you know that you want to sell options when there is a lot of fear. And as you know, there was no shortage of fear back then.
I remember talking to Porter about blue-chip stocks that paid insanely high premiums if you sold their options.
Eventually I convinced Porter about selling options because I showed him that it was exactly what I was doing with my own money. And it was working.
So he started doing it himself... and we even went so far as to launch one of the very first put-selling trading advisories geared toward everyday investors – the Put Strategy Report.
When the crisis passed, I retooled the strategy to earn generous returns even when the market wasn't in crisis, and we launched it as Retirement Trader in 2010.
Since then, my team and I have created Income Intelligence, an income-focused advisory where we share many different ways to collect safe and large income payments... And we also created Advanced Options just a few years ago, an options-trading service where we trade something called "spreads" – trying to earn triple-digit gains in just a matter of weeks.
My team has grown over the years as well. I have analysts like Jeff, who has an MBA... I have a chartered financial analyst on the team, as well as a certified financial planner.
As we are coming to the end of 2021, it's hard not to look back at all my years at Stansberry Research and be thankful. It's notes from subscribers saying that our work has been beneficial to them that has kept me going for this long.
And I'm excited for the future of Stansberry Research, too.
We have an amazing team and some of the smartest minds in finance. We've recently brought on editors like Matt McCall and cryptocurrency expert Eric Wade. Both of these analysts' track records speak for themselves. (Eric has an open crypto recommendation that is up by 2,861% at the moment.)
Stansberry Research has grown along with the needs of its readers.
If you've enjoyed my work and the work of everyone else at Stansberry, we are currently offering the opportunity to become a "Partner" in our business. Basically, if you want to become more than a regular subscriber, we're offering a lifetime stake in our research.
You can get all the details by watching our special end-of-year broadcast that just went live today.
During the broadcast, we also discussed some important changes we've made to our business... and how it could all benefit you personally.
What We're Reading...
- IEA: Omicron to temporarily slow global oil demand recovery.
- Something different: Warriors' Stephen Curry on brink of NBA's career 3-point record.
Here's to our health, wealth, and a great retirement,
Dr. David Eifrig and the Health & Wealth Bulletin Research Team
December 15, 2021